Conference abstract · 15 Apr 2019
Conference abstractPublished 26 Oct 2015
Biosimilar development and production
Theramyt Novobiologics, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biosimilars are increasingly being developed by many companies and used as therapeutics for various diseases worldwide. There is a lot of scope to improve in biosimilar story. Biosimilar products are approved through stringent regulatory pathways in highly regulated markets such as the US, EU, Japan, Canada and Australia following loss of exclusivity of their originator reference product. The development of biosimilar product possesses various challenges such as comparable quality, safety and efficacy to a reference product in addition to other challenges in product development from laboratory to manufacturing scale. Biosimilar from process development, pre-clinical trials and clinical trials upto fill finish meets number of challenges. Quality attributes of monoclonal antibody or bio-therapeutic proteins are highly affected by both process and product related impurities. There should be an efficient upstream as well as downstream process to overcome all the bottlenecks and establishing appropriate standards for biosimilarity remains an important area for scientific, legislative and regulatory debate. I would like to give an overview on biosimilar development in various countries and current scenario. My discussion is intended for audience from biopharma industry as well as from active collaborators from various institutes and universities.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 19 Oct 2016
Systematic Shortlisting of Candidate Molecules and Biosimilar/Biobetter Product Development: An Undergraduate Research Effort
Review article · 26 Jul 2016
Regulatory strategy for the development of analytical methods for the routine determination of aggregate profiles for a biosimilar product
Conference abstract · 27 Jun 2016
Cell line development for the production of biosimilar monoclonal antibodies with high target bioactivity and high productivity
Conference abstract · 25 Sep 2014
Production of biosimilars in developing countries: Challenges and opportunities: SEDICO case Study
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Vivek Halan”
